UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 11, 2014
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
333-148922 |
26-0690857 |
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
IRS Employer
Identification No.) |
655 Montgomery Street
Suite 900
San Francisco, CA |
94111 |
(Address of Principal Executive Offices) |
(Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 |
Other Events
On December 11, 2014, Amarantus
Bioscience Holdings, Inc. (the “Company”) issued a press release appointing Elise Brownell, Ph.D., as Senior Vice
President of Operations and Project Management. The press release is attached as Exhibit 99.1 to this report on Form 8-K
and is incorporated herein by reference. |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
|
|
|
99.1 |
|
Press Release dated December 11, 2014 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
Date: December 11, 2014 |
By: |
/s/ Gerald E. Commissiong |
|
|
|
|
Name: Gerald E. Commissiong |
|
|
|
|
Title: Chief Executive Officer |
|
Amarantus
Appoints Elise Brownell, Ph.D. as Senior Vice President of Operations and Project Management
SAN FRANCISCO, CA and GENEVA, SWITZERLAND – December 11,
2014 - Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a
biotechnology company focused on the development of diagnostics and therapeutic products in the areas of neurology, psychiatry,
ophthalmology and regenerative medicine, announced the appointment of Elise Brownell, Ph.D. to the newly created position of Senior
Vice President of Operations and Program Management.
“It is my great pleasure to welcome Dr. Brownell to the
Amarantus executive management team,” commented Gerald E. Commissiong, President & CEO of Amarantus. “This is a
key appointment and exemplary of our commitment to operational excellence. Elise will play an integral role for the company with
her ‘hands-on’ approach and vast global management experience. Her leadership and insight will be a huge asset to the
team. Importantly, Elise’s impressive drug development and project management expertise will be essential as we advance both
Eltoprazine and ESS-W into Phase 2 clinical studies in the first half of 2015.”
Dr. Brownell brings more than 20 years of biotechnology and
pharmaceutical project management experience with a proven track record of advancing programs through clinical development. She
serves as a Life Sciences entrepreneurial advisor for ASTIA, the nation's premier entrepreneurial organization focused on women-led
businesses. Dr. Brownell is also a member of the Editorial Advisory Board for Contract Pharma Magazine, and previous Chair of the
Leaders Network program of Women in Consulting.
“Amarantus is a truly exciting company with several potential
blockbuster product candidates targeting significant unmet needs,” stated Dr. Brownell. “I look forward to working
closely with this team of visionaries with the goal of providing new, paradigm-changing treatment options for patients.”
Dr. Brownell is the co-founder of ZephyrBiotech, LLC. a project
management firm dedicated to advancing therapeutic candidates through development to key inflection points for clients. Earlier,
she was a founding member, head of project management and senior director of Aerovance, Inc, a venture-backed biotechnology company
spun out from Bayer Healthcare, where she created and managed effective team processes to bring product candidates into full scale
clinical Phase 1 and 2 development. Prior to Aerovance, Dr. Brownell acted as head of project management for Bayer's Biotechnology
Unit, where she integrated project strategies to meet therapeutic and market needs. Other roles included building and negotiating
partnerships with third parties to support development programs leading research teams through early bench-to-clinic development
phases, as well as entrepreneurial investment experience with Angel’s Forum (www.angelsforum.com). Dr. Brownell received
her M.S., M.Phil. and Ph.D. in biology from Yale University and her B.S. in biology from Allegheny College.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's disease Levodopa
induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®"),
which was developed by Prof. Thomas Arendt, Ph.D. from the University of Leipzig, for Alzheimer's disease and owns the intellectual
property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is
developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns intellectual property for the diagnosis
of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard™"). In November
2014, AMBS entered into an exclusive option agreement with Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd., to acquire
Cutanogen Corporation, a subsidiary of Lonza Walkersville, to develop Engineered Skin Substitute (ESS-W), an autologous skin replacement
product for the treatment of Stage 3 and Stage 4 intractable severe burns. For further information please visit www.Amarantus.com,
or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are
identified by the words "believes," "project," "expects," "anticipates," "estimates,"
"intends," "strategy," "plan," "may," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions. Forward-looking statements are based on current
expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from
the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include,
but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates,
competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating
forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Shareholder Contact:
Aimee Boutcher, Investor Relations
T: (US) 408.737.2734 x 101
E: ir@amarantus.com
Media Contact:
Planet Communications
Deanne Eagle, Media Contact
T: (US) 917.837.5866
Source: Amarantus Bioscience Holdings, Inc.
###
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024